Bristol-Myers Squibb

COVID-19 prompts Pfizer to stop enrollment in most studies
COVID-19 prompts Pfizer to stop enrollment in most studies
Fierce Pharma
Pfizer
Bristol-Myers Squibb
Eli Lilly
R&D
clinical trials
COVID-19
Flag link:
Go or no go? Covid-19 upstages US regulatory decisions
Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
FDA
regulatory
Bristol-Myers Squibb
ozanimod
Esteve
E-58425
Fabre-Kramer
AstraZeneca
Imfinzi
Astellas
Vesicare
AbbVie
Neurocrine
Orlissa
Sanofi
MenQuadfi
opicapone
Acceleron
Reblozyl
Flag link:
Janssen files MS pill, ahead of FDA decision on BMS’ rival
Janssen files MS pill, ahead of FDA decision on BMS’ rival
Pharmaforum
Janssen
JNJ
multiple sclerosis
MS
FDA
ponesimod
Bristol-Myers Squibb
ozanimod
Flag link:
Bristol Myers CEO Caforio hires a top investment banker from Barclays for his next BD/strategy chief
Bristol Myers CEO Caforio hires a top investment banker from Barclays for his next BD/strategy chief
Endpoints
Bristol-Myers Squibb
M&A
Giovanni Caforio
Flag link:
With Bristol and Otsuka on Board, LSP Raises $620M EU Life Sciences Fund
With Bristol and Otsuka on Board, LSP Raises $620M EU Life Sciences Fund
Xconomy
LSP
life sciences
Bristol-Myers Squibb
Otsuka
Europe
Flag link:
Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo
Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo
Fierce Pharma
Bristol-Myers Squibb
Opdivo
Yervoy
FDA
liver cancer
hepatocellular carcinoma
Flag link:
2 newer multiple myeloma drugs fall short in bid for wider market
2 newer multiple myeloma drugs fall short in bid for wider market
BioPharma Dive
Multiple Myeloma
clinical trials
Bristol-Myers Squibb
Takeda
Ninlaro
Empliciti
Revlimid
Flag link:
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
Flag link:
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Endpoints
Bristol-Myers Squibb
Celgene
M&A
clinical trials
Multiple Myeloma
Empliciti
AbbVie
Revlimid
Flag link:
Big Pharma grounds employees: GSK, Bristol, Roche, Sanofi and more limit travel due to coronavirus
Big Pharma grounds employees: GSK, Bristol, Roche, Sanofi and more limit travel due to coronavirus
Fierce Pharma
COVID-19
coronaviruses
Roche
GSK
Bristol-Myers Squibb
Sanofi
Boehringer Ingelheim
Amgen
Biogen
Mylan
Flag link:
BMS joins with Voluntis to create cancer support app
BMS joins with Voluntis to create cancer support app
Pharmaforum
Bristol-Myers Squibb
Voluntis
cancer
mobile apps
Flag link:
Bristol Myers Squibb unveils new branding, will phase out Celgene brand
Bristol Myers Squibb unveils new branding, will phase out Celgene brand
Medical Marketing and Media
Bristol-Myers Squibb
Celgene
rebranding
M&A
Flag link:
Bristol-Myers Squibb reaches tentative deal to end long-running Medicaid rebate lawsuit
Bristol-Myers Squibb reaches tentative deal to end long-running Medicaid rebate lawsuit
Fierce Pharma
Bristol-Myers Squibb
Medicaid
Flag link:
Go or no go? Ozanimod and Fintepla await FDA verdicts
Go or no go? Ozanimod and Fintepla await FDA verdicts
EP Vantage
Bristol-Myers Squibb
ozaminod
MS
multiple sclerosis
Zogenix
Fintepla
FDA
Flag link:
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Motley Fool
beta thalassemia
rare disease
drug development
Acceleron
Bristol-Myers Squibb
Bluebird Bio
Sangamo Therapeutics
Vertex Pharmaceuticals
Editas Medicine
Syros Pharmaceuticals
Flag link:
A Big Month Ahead for the FDA and Bristol-Myers Squibb
A Big Month Ahead for the FDA and Bristol-Myers Squibb
Motley Fool
Bristol-Myers Squibb
Celgene
FDA
ozanimod
Opdivo
Reblozyl
Flag link:
Five Prime Therapeutics’ pancreatic cancer combo with Opdivo a bust
Five Prime Therapeutics’ pancreatic cancer combo with Opdivo a bust
Fierce Biotech
Five Prime Therapeutics
cabiralizumab
Bristol-Myers Squibb
Opdivo
pancreatic cancer
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
Opdivo delivers superior five-year survival results in renal cell carcinoma
Opdivo delivers superior five-year survival results in renal cell carcinoma
Pharmaceutical Business Review
Bristol-Myers Squibb
Opdivo
clinical trials
renal cell carcinoma
Flag link:
Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date
Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date
Fierce Biotech
Bristol-Myers Squibb
FDA
lisocabtagene maraleucel
priority review
CAR-T
Flag link:

Pages